Seyed Alireza Rabi, M.D.,Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
HIV-1 | 16 | 2017 | 6931 | 0.630 |
Why?
|
Virus Internalization | 4 | 2022 | 499 | 0.500 |
Why?
|
CD4-Positive T-Lymphocytes | 11 | 2017 | 4374 | 0.470 |
Why?
|
HIV Protease | 1 | 2013 | 96 | 0.460 |
Why?
|
HIV Long-Term Survivors | 2 | 2011 | 126 | 0.460 |
Why?
|
HIV Protease Inhibitors | 3 | 2013 | 435 | 0.420 |
Why?
|
Virus Replication | 8 | 2017 | 2529 | 0.400 |
Why?
|
Drug Resistance, Viral | 2 | 2013 | 829 | 0.400 |
Why?
|
Virus Latency | 6 | 2017 | 356 | 0.310 |
Why?
|
Antiretroviral Therapy, Highly Active | 6 | 2012 | 1896 | 0.270 |
Why?
|
env Gene Products, Human Immunodeficiency Virus | 2 | 2013 | 363 | 0.190 |
Why?
|
Heart Transplantation | 2 | 2023 | 3109 | 0.180 |
Why?
|
Anti-HIV Agents | 5 | 2013 | 4320 | 0.160 |
Why?
|
HIV Infections | 11 | 2013 | 16764 | 0.160 |
Why?
|
RNA, Viral | 3 | 2022 | 2907 | 0.150 |
Why?
|
Tissue and Organ Procurement | 1 | 2023 | 891 | 0.130 |
Why?
|
Simian Acquired Immunodeficiency Syndrome | 2 | 2010 | 570 | 0.130 |
Why?
|
HIV | 2 | 2012 | 1607 | 0.120 |
Why?
|
Cardiac Glycosides | 1 | 2013 | 30 | 0.120 |
Why?
|
Anti-Retroviral Agents | 3 | 2012 | 1734 | 0.120 |
Why?
|
Virus Release | 1 | 2013 | 39 | 0.120 |
Why?
|
Virus Attachment | 1 | 2013 | 55 | 0.120 |
Why?
|
Proviruses | 2 | 2012 | 316 | 0.110 |
Why?
|
Immunologic Memory | 2 | 2017 | 1348 | 0.110 |
Why?
|
Virion | 2 | 2011 | 435 | 0.110 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 3 | 2017 | 4743 | 0.100 |
Why?
|
Virus Activation | 1 | 2013 | 319 | 0.100 |
Why?
|
DNA, Viral | 3 | 2012 | 2223 | 0.090 |
Why?
|
Transcription, Genetic | 2 | 2017 | 7709 | 0.090 |
Why?
|
Viral Load | 3 | 2013 | 3299 | 0.090 |
Why?
|
T-Lymphocytes, Cytotoxic | 2 | 2017 | 1822 | 0.080 |
Why?
|
Fluorescence Resonance Energy Transfer | 1 | 2010 | 403 | 0.080 |
Why?
|
Oligopeptides | 1 | 2013 | 1179 | 0.080 |
Why?
|
Simian immunodeficiency virus | 2 | 2010 | 846 | 0.070 |
Why?
|
Tissue Donors | 3 | 2023 | 2205 | 0.070 |
Why?
|
Drug Combinations | 1 | 2012 | 1959 | 0.070 |
Why?
|
Biological Evolution | 1 | 2012 | 1072 | 0.070 |
Why?
|
Genes, Reporter | 1 | 2010 | 1549 | 0.070 |
Why?
|
Staining and Labeling | 1 | 2010 | 1108 | 0.070 |
Why?
|
Dose-Response Relationship, Drug | 3 | 2013 | 10945 | 0.070 |
Why?
|
Central Nervous System Diseases | 1 | 2010 | 522 | 0.070 |
Why?
|
Models, Biological | 2 | 2012 | 9609 | 0.060 |
Why?
|
Green Fluorescent Proteins | 1 | 2010 | 2092 | 0.060 |
Why?
|
Drug Therapy, Combination | 2 | 2012 | 6478 | 0.060 |
Why?
|
Acquired Immunodeficiency Syndrome | 1 | 2013 | 2241 | 0.060 |
Why?
|
HEK293 Cells | 1 | 2013 | 4174 | 0.060 |
Why?
|
Mutation, Missense | 1 | 2013 | 2552 | 0.060 |
Why?
|
Bone Marrow Cells | 1 | 2012 | 2515 | 0.060 |
Why?
|
Sulfonamides | 1 | 2013 | 1934 | 0.060 |
Why?
|
Cells, Cultured | 3 | 2017 | 19220 | 0.050 |
Why?
|
Monocytes | 1 | 2011 | 2583 | 0.050 |
Why?
|
Pyridines | 1 | 2013 | 2810 | 0.050 |
Why?
|
Guanidines | 1 | 2022 | 191 | 0.050 |
Why?
|
Esters | 1 | 2022 | 210 | 0.050 |
Why?
|
Brain Death | 1 | 2023 | 346 | 0.050 |
Why?
|
Hematopoietic Stem Cells | 1 | 2012 | 3364 | 0.040 |
Why?
|
Heart Failure | 1 | 2023 | 10793 | 0.040 |
Why?
|
Death | 1 | 2023 | 670 | 0.040 |
Why?
|
Lymphocyte Activation | 3 | 2017 | 5522 | 0.040 |
Why?
|
Protease Inhibitors | 1 | 2022 | 792 | 0.040 |
Why?
|
Humans | 21 | 2023 | 739398 | 0.040 |
Why?
|
Macrophages | 1 | 2011 | 5631 | 0.030 |
Why?
|
Feces | 1 | 2022 | 1389 | 0.030 |
Why?
|
Gastrointestinal Tract | 1 | 2022 | 814 | 0.030 |
Why?
|
Disease Progression | 1 | 2011 | 13237 | 0.030 |
Why?
|
Receptors, HIV | 1 | 2013 | 162 | 0.030 |
Why?
|
Graft Survival | 1 | 2023 | 3723 | 0.030 |
Why?
|
Cytopathogenic Effect, Viral | 1 | 2012 | 156 | 0.030 |
Why?
|
Integrase Inhibitors | 1 | 2011 | 12 | 0.030 |
Why?
|
Drug Repositioning | 1 | 2013 | 232 | 0.030 |
Why?
|
Genetic Fitness | 1 | 2012 | 121 | 0.020 |
Why?
|
Receptors, CCR5 | 1 | 2013 | 497 | 0.020 |
Why?
|
Protein Interaction Domains and Motifs | 1 | 2013 | 473 | 0.020 |
Why?
|
Inflammation | 1 | 2010 | 10534 | 0.020 |
Why?
|
Antigens, CD34 | 1 | 2012 | 656 | 0.020 |
Why?
|
Antiviral Agents | 1 | 2022 | 2971 | 0.020 |
Why?
|
Cytokines | 2 | 2017 | 7298 | 0.020 |
Why?
|
Virus Integration | 1 | 2011 | 297 | 0.020 |
Why?
|
Inhibitory Concentration 50 | 1 | 2009 | 464 | 0.020 |
Why?
|
Gene Expression Regulation, Viral | 1 | 2011 | 441 | 0.020 |
Why?
|
Receptors, CXCR4 | 1 | 2013 | 726 | 0.020 |
Why?
|
Host-Pathogen Interactions | 1 | 2017 | 1476 | 0.020 |
Why?
|
Gene Expression Profiling | 2 | 2017 | 9387 | 0.020 |
Why?
|
DNA Primers | 1 | 2013 | 2893 | 0.020 |
Why?
|
Cytotoxicity, Immunologic | 1 | 2012 | 1369 | 0.020 |
Why?
|
Coculture Techniques | 1 | 2012 | 1343 | 0.020 |
Why?
|
Species Specificity | 1 | 2012 | 2480 | 0.020 |
Why?
|
Macaca | 1 | 2009 | 443 | 0.020 |
Why?
|
Reverse Transcriptase Inhibitors | 1 | 2011 | 624 | 0.020 |
Why?
|
High-Throughput Screening Assays | 1 | 2013 | 953 | 0.020 |
Why?
|
Lymphocyte Count | 1 | 2009 | 791 | 0.020 |
Why?
|
Flow Cytometry | 1 | 2017 | 5959 | 0.020 |
Why?
|
Viremia | 1 | 2009 | 733 | 0.020 |
Why?
|
Cell Death | 1 | 2011 | 1693 | 0.020 |
Why?
|
Rats | 1 | 2022 | 24270 | 0.020 |
Why?
|
Adaptive Immunity | 1 | 2010 | 709 | 0.020 |
Why?
|
Epitopes | 1 | 2011 | 2558 | 0.020 |
Why?
|
HIV Antibodies | 1 | 2011 | 1309 | 0.020 |
Why?
|
Disease Susceptibility | 1 | 2011 | 1778 | 0.020 |
Why?
|
Phylogeny | 1 | 2011 | 2789 | 0.020 |
Why?
|
Macaca mulatta | 1 | 2010 | 2384 | 0.010 |
Why?
|
Lung | 1 | 2022 | 9782 | 0.010 |
Why?
|
Antibodies, Neutralizing | 1 | 2011 | 1957 | 0.010 |
Why?
|
Bone Marrow | 1 | 2012 | 2933 | 0.010 |
Why?
|
Risk Assessment | 1 | 2023 | 23294 | 0.010 |
Why?
|
Protein Binding | 1 | 2013 | 9375 | 0.010 |
Why?
|
Time Factors | 1 | 2023 | 40050 | 0.010 |
Why?
|
Medication Adherence | 1 | 2012 | 2047 | 0.010 |
Why?
|
Amino Acid Sequence | 1 | 2011 | 13816 | 0.010 |
Why?
|
Cohort Studies | 2 | 2013 | 40389 | 0.010 |
Why?
|
Cell Line | 1 | 2013 | 15987 | 0.010 |
Why?
|
Animals | 3 | 2022 | 168368 | 0.010 |
Why?
|
Computer Simulation | 1 | 2012 | 6237 | 0.010 |
Why?
|
Molecular Sequence Data | 1 | 2011 | 18125 | 0.010 |
Why?
|
Immunity, Innate | 1 | 2010 | 2950 | 0.010 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2011 | 4424 | 0.010 |
Why?
|
Lymph Nodes | 1 | 2009 | 3454 | 0.010 |
Why?
|
Chronic Disease | 1 | 2011 | 9133 | 0.010 |
Why?
|
Male | 4 | 2017 | 349022 | 0.010 |
Why?
|
Retrospective Studies | 1 | 2023 | 76631 | 0.010 |
Why?
|
Adult | 2 | 2023 | 213394 | 0.010 |
Why?
|
Phenotype | 1 | 2011 | 16301 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2011 | 19811 | 0.010 |
Why?
|
Algorithms | 1 | 2012 | 13872 | 0.010 |
Why?
|
Disease Models, Animal | 1 | 2009 | 18003 | 0.010 |
Why?
|
Mutation | 1 | 2012 | 29658 | 0.000 |
Why?
|
Middle Aged | 2 | 2012 | 212863 | 0.000 |
Why?
|
Female | 2 | 2017 | 378853 | 0.000 |
Why?
|
Treatment Outcome | 1 | 2012 | 62693 | 0.000 |
Why?
|
Aged | 1 | 2012 | 162698 | 0.000 |
Why?
|